1,329 calculators and references across 60 specialties, with formula confidence shown up front.
AWARD-Class / PARADIGM-HF Responder context and interpretation The AWARD-Class score (derived from a two-center real-world cohort) is an easy-to-calculate index intended to predict a 1-year “super-response” to sacubitril/valsartan, defined in the derivation study as absence of HF admission/transplant/death plus either ≥50% NT-proBNP reduction and/or ≥10-point increase in LVEF. The score uses six routinely available c
— Explanation and Clinical Context PARADISE-MI was a multinational randomized trial that enrolled high-risk patients early after acute myocardial infarction if they had transient pulmonary congestion or LVEF ≤40% and at least one additional risk factor (age ≥70 years, eGFR <60 mL/min/1.73 m², diabetes, prior myocardial infarction, atrial fibrillation, LVEF <30%, Killip class ≥III, or STEMI without reperfusion). The t
PARAGON-HF Response Score: Explanation and Clinical Context The PARAGON-HF Response Score is an exploratory model derived from the PARAGON-HF trial, developed to identify patients with heart failure with preserved ejection fraction (HFpEF) who are most likely to experience clinical and biomarker improvement with sacubitril/valsartan therapy. This score integrates demographic and clinical parameters — including age, s
The audited source currently returns an empty page. This catalog entry is retained for coverage and monitoring, but no clinical content or calculation is asserted.
PIONEER-AF-PCI Bleeding Algorithm: Explanation and Clinical Context The PIONEER-AF-PCI trial randomized patients with nonvalvular atrial fibrillation who underwent PCI with stent placement to one of three antithrombotic strategies and measured clinically significant bleeding at 12 months. The trial found lower rates of clinically significant bleeding in two rivaroxaban-based strategies compared with standard therapy
PREDICT-HF Risk Score: Explanation and Clinical Context The PREDICT-HF model (PARADIGM Risk of Events and Death in Contemporary Treatment of Heart Failure) was derived in patients enrolled in the PARADIGM‑HF trial (n ≈ 8,011) with chronic heart failure with reduced ejection fraction, and was subsequently validated in the ATMOSPHERE trial population and in the Swedish Heart Failure Registry (SwedeHF). Key baseline pre
: Explanation and Clinical Context The PROLONG study examined patients with newly diagnosed heart failure and an initial left ventricular ejection fraction (LVEF) ≤35% who were protected temporarily by a wearable cardioverter-defibrillator (WCD) while guideline-directed medical therapy was initiated and optimized. The study defined criteria under which prolongation of the WCD wearing period — rather than immediate im
PROVE-HF Biomarker Improvement Algorithm — Explanation and Clinical Context The PROVE-HF (Prospective Study of Biomarkers, Symptom Improvement, and Ventricular Remodeling During Sacubitril/Valsartan Therapy for Heart Failure) program examined whether changes in NT-proBNP after initiation of sacubitril/valsartan are associated with reverse cardiac remodeling and improvements in LV function. In the published cohort (Ja